Highlights Newsletter 3
This newsletter presents you the following key sessions:
2. Larotrectinib active and well tolerated in patients with TRK fusion-positive primary CNS tumours
This newsletter presents you the following key sessions:
2. Larotrectinib active and well tolerated in patients with TRK fusion-positive primary CNS tumours
Medical writer
Medical writer